2021 Revenues ($USD) : $29,113,364,894
2021 Revenues (foreign currencies) : JP¥3,197,812,000,000
2021 R&D spend : $4,149,672,251
2021 Number of Employees : 47,099
Fiscal Year End : 3/31/2021
Leader : CEO Christophe Weber

The Japanese pharma giant has a presence in roughly 80 countries and draws nearly half of its revenue from the U.S. The company continues to have a robust pipeline of approximately 40 clinical-stage assets. In late 2021, the company won FDA approval for Livtencity (maribavir) for refractory post-transplant cytomegalovirus (CMV) infection, marking the second new molecular entity approval in the fiscal year of 2021. The company also won approval for Exkivity (mobocertinib), presently indicated to treat epidermal growth factor receptor (EGFR) exon20 insertion mutation-positive metastatic non-small cell lung cancer. In February 2022, the company won FDA approval for Takhzyro ((lanadelumab-flyo) injection single-dose prefilled syringe to prevent hereditary angioedema in individuals at least 12. In December 2021, however, Takeda received a complete response letter from the FDA for TAK-721 (budesonide oral suspension) as a potential treatment for eosinophilic esophagitis (EoE). —BB